Nicholas Robert
Overview
Explore the profile of Nicholas Robert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robert N, Chen C, Doan J, Venkatasetty D, Espirito J, Aguilar K
Future Oncol
. 2025 Jan;
21(1):83-94.
PMID: 39810652
Aims: To investigate real-world treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who initiated first-line palbociclib-fulvestrant. Patients & Methods: Retrospective...
2.
Saputri F, Robert N, Akbar A
PLoS One
. 2024 Dec;
19(12):e0314922.
PMID: 39642147
The urgency of addressing climate change, exacerbated by greenhouse gas emissions, necessitates sustainable solutions, including green building practices and renewable energy adoption. This study focuses on the feasibility of implementing...
3.
Lund J, Webster-Clark M, Westreich D, Sanoff H, Robert N, Frytak J, et al.
Epidemiology
. 2024 Jan;
35(2):241-251.
PMID: 38290143
Background: In the presence of effect measure modification, estimates of treatment effects from randomized controlled trials may not be valid in clinical practice settings. The development and application of quantitative...
4.
Robert N, Chen C, Kim S, Zhang Z, Aguilar K, Wang Y, et al.
Future Oncol
. 2024 Jan;
20(12):761-780.
PMID: 38231045
Provide real-world data on palbociclib as evidence of effectiveness in patient populations from routine clinical practice. This was a retrospective, observational cohort study of patients with HR+/HER2- metastatic breast cancer...
5.
Goldschmidt J, Chou L, Chan P, Chen L, Robert N, Kinsey J, et al.
Cancer Med
. 2023 Nov;
12(22):20783-20797.
PMID: 37962239
Background: Patient survival in advanced/metastatic melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) has improved with immune checkpoint inhibitors (ICI). Biomarkers' role in prognosis and treatment has...
6.
Zu K, Arunachalam A, Hohlbauch A, Silver M, Robert N
Immunotherapy
. 2023 Sep;
15(16):1375-1387.
PMID: 37694560
This study examined real-world treatment patterns for extensive-stage small-cell lung cancer (ES-SCLC) after immune checkpoint inhibitors (ICIs) became available for frontline use. Adult patients with ES-SCLC initiating 1L systemic treatment...
7.
Nadler E, Vasudevan A, Wentworth C, Robert N, Penrod J, Fiore J, et al.
Future Oncol
. 2023 Sep;
19(26):1785-1800.
PMID: 37665271
Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer. We examined the real-world relationship between these end points in patients with resectable stage...
8.
Yasenchak C, Liu N, Beeks A, Fanale M, Robert N, He D, et al.
JCO Oncol Pract
. 2023 Aug;
19(10):860-870.
PMID: 37651672
Purpose: To evaluate the use of interim positron emission tomography-computed tomography (PET-CT) scans and Deauville 5-point scale (5PS) score reporting for stage III/IV classic Hodgkin lymphoma (cHL) treated frontline (1L)...
9.
Waterhouse D, Yong C, Frankart A, Brannman L, Mulrooney T, Robert N, et al.
Future Oncol
. 2023 Jul;
19(28):1905-1916.
PMID: 37497677
For eligible patients with unresectable stage III non-small-cell lung cancer, durvalumab consolidation therapy following chemoradiotherapy is the standard of care. This was a retrospective study of durvalumab-treated patients diagnosed between...
10.
DeMichele A, Robert N, Chen C, Kim S, Zhang Z, Lu D, et al.
Target Oncol
. 2023 Jul;
18(4):543-558.
PMID: 37428347
Background: Limited real-world data exist regarding the efficacy of palbociclib in combination with endocrine therapy in pre/perimenopausal women with metastatic breast cancer. Objective: We aimed to compare real-world tumor responses...